GP方案胰腺区域性动脉灌注治疗晚期胰腺癌的临床观察  

Clinical Observation of Transarterial Infusion Chemotherapy of GP for Treatment of Advanced Pancreatic Carcinoma

作　　者：刘华强[1] 李勇[1] 黄瑞文[1] 黄晓萍[1] 

机构地区：[1]广东省农垦中心医院,广东湛江524002

出　　处：《肿瘤基础与临床》2008年第6期479-481,共3页journal of basic and clinical oncology

摘　　要：目的比较GP方案胰腺区域性动脉灌注与静脉化疗治疗晚期胰腺癌的疗效与毒副反应。方法将53例晚期胰腺癌采用信封抽签法随机分为胰腺区域性动脉灌注组26例和静脉化疗组27例,平均化疗2.6个周期。结果胰腺区域性动脉灌注组有效率为53.85%(14/26),中位缓解期为10个月,中位生存期为21个月;静脉化疗组有效率为33.33%(9/27),中位缓解期为6.5个月,中位生存期为14个月。胰腺区域性动脉灌注组有效率、中位缓解期及中位生存期均高于静脉化疗组,差异有统计学意义(P<0.05)。胰腺区域性动脉灌注组白细胞及血小板减少发生率分别为61.54%(16/26)、42.31%(11/26),静脉化疗组分别为77.78%(21/27)、59.26%(16/27),两组比较差异均有统计学意义(P<0.05)。结论GP方案胰腺区域性动脉灌注是治疗晚期胰腺癌的有效方案,且毒副反应可耐受。Objective To compare the efficacy and toxicity of infusion of GP, through artery or through vein, to treat advanced pancreatic carcinoma. Methods 53 patients with advanced pancreatic carcinoma were divided into two groups. Chemotherapy averaging 2.6 cycles. Results Response rate was 53.85% （ 14/26）, median time of progression was 10 months, median survival time was 21 months, leukopenia rate was 61.54 % （ 16/26 ）, thrombocytopenia rate was 42.31% （ 11/26） in infusion-through-artery group, while those in infusion-throughvein group were 33.33% （9/27）, 6.5 mths, 14 mths , 77.75% （21/27） , 59.26% （16/27） , respectively. All were significant difference between two groups（P 〈 0.05）. Conclusion To treat patients with advanced pancreatic carcinoma, transarterial infusion chemotherapy of GP was more effective, the toxicity was endurable.

关 键 词：胰腺肿瘤 动脉灌注化疗 吉西他滨 

分 类 号：R730.53[医药卫生—肿瘤] R735.9[医药卫生—临床医学]